Bionova Scientific Introduces COVID-19 Support Program

Bionova Scientific, a biologics CDMO, introduced a COVID-19 support program, making lab capacity available to industry partners impacted by COVID-19 shutdowns. Organizations developing COVID-19 related treatments will be given priority access through the program.

"We recognize that the capacity of the industry we serve has been severely impacted by this crisis. Meanwhile, the development timelines for new therapeutics remain as urgent as ever," said Bionova CEO Amy Kong. "This has coincided with an expansion of our lab capacity for the development and production of mAbs and recombinant proteins, so we want to let potential partners know that our critical lab functions are fully operational and available to keep their programs on track."

Bionova Vice President of Business Development, Bruce Frazier, added, "We have a team and facility that deliver the highest quality CDMO services, as demonstrated by our customer loyalty here in the Bay Area. We are hoping we can act as a relief valve for companies that are struggling to find capable resources for their critical projects during this challenging time."

Register as Visitor to CPhI China 2020!

-----------------------------------------------------------------------
Editor's Note:

En-CPhI.CN is a vertical B2B online trade platform serving the pharmaceutical industry,

for any copyright disputes involved in the articles,

please email: Julia.Zhang@imsinoexpo.com to motify or remove the content.